Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer^*

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717.
   PubMed Web of Science ®Google Scholar
• Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys. 2008;72:972–979.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–2027.
   PubMed Web of Science ®Google Scholar
• Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329–2335.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. JCO. 2009;27:2924–2930.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71:618–629.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol. 2001;166:2185–2188.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76:361–368.
   PubMed Web of Science ®Google Scholar
• Ervandian M, Hoyer M, Petersen SE, et al. Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncol. 2016;55:598–603.
   PubMed Web of Science ®Google Scholar
• Petersen ES. Long term morbidity after external beam radiation therapy or radical prostatectomy for prostate cancer? Forthcoming, 2014.
   Google Scholar
• Hansen BJ, Flyger H, Brasso K, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol. 1995;76:451–458.
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
   PubMed Web of Science ®Google Scholar
• Dubbelman YD, Bosch JL. Urethral sphincter function before and after radical prostatectomy: systematic review of the prognostic value of various assessment techniques. Neurourol Urodyn. 2013;32:957–963.
   PubMed Web of Science ®Google Scholar
• Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84:121–127.
   PubMed Web of Science ®Google Scholar
• Bolla M. The potential impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol. 2014;65:552–553.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Fischedick K, Asadpour B, et al. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis. Radiother Oncol. 2008;88:135–139.
   PubMed Web of Science ®Google Scholar
• Van Cangh PJ, Richard F, Lorge F, et al. Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study. J Urol. 1998;159:164–166.
   PubMed Web of Science ®Google Scholar
• Petroski RA, Warlick WB, Herring J, et al. External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence. Prostate Cancer Prostatic Dis. 2004;7:170–177.
   PubMed Web of Science ®Google Scholar
• Adam M, Tennstedt P, Lanwehr D, et al. Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy. Eur Urol. 2017;71:330–336.
   PubMed Web of Science ®Google Scholar
• Suardi N, Gallina A, Lista G, et al. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. Eur Urol. 2014;65:546–551.
   PubMed Web of Science ®Google Scholar
• Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1417–1423.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, van Cangh PJ, , et al. Acute and late toxicity of post-operative external irradiation in PT3N0 prostate cancer patients within EORTC trial 22911. Radiat Oncol 2002;54:(Suppl):62–63.
   Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Hayden KA, Unger JM, et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. JCO. 2008;26:112–120.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Drevin L, Loeb S, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117:E36–E45.
   PubMed Web of Science ®Google Scholar
• van Stam MA, Aaronson NK, Pos FJ, et al. The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients. Eur Urol. 2016;70:751–757.
   PubMed Web of Science ®Google Scholar
• Juul T, Petersen MA, Holzner B, et al. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res. 2014;23:2183–2193.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. Discussion 14–5.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956–962.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.radicals-trial.org/; 2017.
   Google Scholar
• Pearse M, Fraser-Browne C, Davis ID, et al. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int. 2014;113 (Suppl 2):7–12.
   PubMed Web of Science ®Google Scholar